Treatment of Acute Myeloblastic Leukemia in Younger Patients

Status Completed

Clinical Trial Summary

study of the value of the cytogenetics and the monitoring of the residual minimum disease in the standard treatment of acute myeloblastic leukemia.

Clinical Trial Description

The treatment scheme is purely welfare and therefore it does not require any approval of ethical committees for his application. It gathers the basic ideas of the present treatment of the AML, with optional induction according to preference of each center with daunorubicin or Idarubicin (x3) associated to AraC (x7). The patients who reach CR consolidate with an identical cycle to the used one in the induction. Later (if pte has identical donor HLA, and as much it as their doctors has preference by this option) receive allogenic transplant. The other patients who reach CR receive two intensifications, one that AraC to intermediate dose contains and another one with autologous transplant, previous preparation with Busulfán, Etoposide and AraC. Later all antileucemic treatment is suspended until possible relapse. This scheme of treatment is accompanied by a valuation of the quality of the CR with traditional morphology, Immunocytometry and molecular genetic study and of a pursuit of residual minimum disease (EMR) using the same techniques. ;

Study Design

Observational Model: Case-Only, Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00390715
Study type	Observational
Source	PETHEMA Foundation
Contact
Status	Completed
Phase	Phase 4
Start date	January 1999
Completion date	January 2010

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04452604` - Multicentric Registry of Patients With Acute Leukemia Infected by COVID-19
Completed	`NCT01041040` - LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)	Phase 4
Completed	`NCT00552825` - Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children	N/A
Recruiting	`NCT01966497` - Observational Study of Patients Older Than 60 Years With Acute Myeloblastic Leukemia	N/A
Active, not recruiting	`NCT01457885` - Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen	Phase 2
Completed	`NCT04082286` - Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia	Phase 1
Completed	`NCT01611116` - Study With Temsirolimus Added to Standard Chemotherapy for Patients Over 60 Years With Acute Myeloblastic Leukemia	Phase 2
Completed	`NCT00504920` - Symptom-Related Cytokines in Acute Myeloblastic Leukemia and Myelodysplastic Syndrome Patients	N/A
Completed	`NCT00354120` - Thymoglobuline Versus Alemtuzumab in Patients Undergoing Allogeneic Transplant	Phase 2/Phase 3
Completed	`NCT03280290` - Transplant T CD4+ CCR7+ In Hematopoietic Stem Cells Allograft	N/A
Completed	`NCT01435343` - Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia	Phase 1/Phase 2
Completed	`NCT00487448` - SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia	Phase 4
Recruiting	`NCT05499611` - Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia
Completed	`NCT05696457` - Effects of Music Therapy in Controlling Symptoms in Patients With AML and Undergoing HSCT	N/A
Recruiting	`NCT01296178` - PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years	N/A
Active, not recruiting	`NCT01307241` - RFC and MTHFR SNPs & hENT1- dCK Expression as Prognostic Factors in ALL & hENT1- dCK Expression as Prognostic Factors in AML	N/A
Completed	`NCT00435864` - Natural Killer Index From Hematopoietic Stem Cell Graft	N/A